Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2010, Vol. 32 ›› Issue (2): 151-156.doi: 10.3881/j.issn.1000-503X.2010.02.005

• Abstracts • Previous Articles     Next Articles

Efficacy and Safety of Erlotinib as Monotherapy for Advanced Non-small Cell Lung Cancer

WANG Meng-zhao1;ZHANG Xiao-tong1;ZHANG Xin-yong2;ZHANG Li1;ZHONG Wei1;XU Li-yan2;LI Long-yun1   

  1. 1Department of Respiratory Medicine,PUMC Hospital, CAMS and PUMC, Beijing 100730, China
    2Department of Medical Oncology, Beijing Chest Hospital, Beijing 101149, China
  • Received:2009-12-28 Revised:1900-01-01 Online:2010-04-30 Published:2010-04-30
  • Contact: WANG Meng-zhao

Abstract: ABSTRACT:Objective To explore the efficacy and safety of erlotinib monotherapy for advanced non-small cell lung cancer (NSCLC). Methods Totally 50 patients with advanced NSCLC received oral erlotinib 150 mg/d treatment, and tumor specimen in 19 patients were collected for epidermal growth factor receptor (EGFR) gene mutation tests. Median survival (MS) was calculated using the Kaplan-Meier method. Results The most common adverse events (AEs) were skin rash (96%) and diarrhea (32%). The overall survival(OS) of all patients was 21.8 months [95% confidential interval (CI): 17.1-26.4 months] and the median progression-free survival (PFS) of all patients was 7.0 months (95% CI: 3.9-10.1 months). EGFR mutation analysis showed gene mutation in 8 cases and wild type in 11 cases. The objective response rate in patients with or without EGFR gene mutations were 62.5% and 9.1%, respectively (χ2=6.631, P=0.036). PFS in patients with or without EGFR gene mutations were 16.330 (95% CI: 2.803-29.857 months) and 5.570 months (95% CI: 2.441-8.699 months), respectively (χ2=8.799, P=0.003). Conclusion Erlotinib monotherapy is safe and effective for some Chinese NSCLC patients after failure of prior chemotherapy.

Key words: non-small cell lunc cancer, erlotinib, epidermal crowtd factor receptor cene mutation